Extension Protocol for Patients With Chronic Myelogenous Leukemia, Malignant Melanoma or Renal Cell Carcinoma That Have Responded to Treatment With Pegylated-Interferon α-2a or Roferon-A® in Prior Clinical Studies
Phase of Trial: Phase II/III
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Interferon alpha-2a (Primary) ; Peginterferon alfa-2a (Primary)
- Indications Chronic myeloid leukaemia; Malignant melanoma; Renal cancer
- Focus Adverse reactions
- Sponsors Roche
- 07 Jul 2016 Status changed from active, no longer recruiting to completed.
- 08 Jun 2006 New trial record.